Annexin announces success in the company's cancer initiative

Contributed by: PR Newswire

Tags

Annexinpharma

More Like This

First patient treated in the second dose group in Annexin's RVO study

Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest Clinical Trial Data

VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval

Omniose Announces Scientific Collaboration With AstraZeneca to Research Vaccines for Serious Bacterial Diseases

BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate

ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR

XNK Therapeutics receives funding from Sweden's innovation agency Vinnova